Opendata, web and dolomites

TITLY SIGNED

Inhibition of the T-cell receptor signalling pathway for treatment of T-cell lymphoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TITLY project word cloud

Explore the words cloud of the TITLY project. It provides you a very rough idea of what is the project "TITLY" about.

led    compounds    louis    bethesda    dismal    came    proliferation    models    btk    15    potency    scientifique    adaptor    named    screen    united    inhibitors    approval    vitro    global    regulatory    gilles    revolutionizing    rnas    lyon    rely    lymphoma    non    recherche    peripheral    rapid    provides    fellowship    science    function    malignancies    exceeding    de    return    11th    lymphomas    lines    cancer    previously    functional    inhibitor    small    hairpin    survival    bruton    potent    branch    group    ie    usa    pharmacological    team    xenograft    lymphoid    mature    10th    treatment    staudt    medical    discovery    salles    tcr    place    translation    kinase    receptor    bcr    works    similarly    perform    national    nhl    form    first    basic    accelerated    share    agencies    barely    cell    pr    ptcl    indolent    researcher    vivo    technic    fruitfully    therapeutic    signalling    france    centre    lab    outgoing    la    worldwide    transformation    granted    mainly    lymphocyte    dr    hodgkin    prognosis    tyrosine    shrnas   

Project "TITLY" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.crcl.fr/638-Salles-genestier.crcl.aspx
 Total cost 178˙603 €
 EC max contribution 178˙603 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-GF
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2017-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 178˙603.00
2    United States Department of Health and Human Services US (Washington D.C.) partner 0.00

Map

 Project objective

Non-Hodgkin lymphoma (NHL) is a form of cancer emerging from the transformation of a mature B- or T-cell lymphocyte. NHL is the 11th most common cancer in Europe, and the 10th most common cancer worldwide. Functional evidence of the key role of B-cell receptor (BCR) signalling in B-cell malignancies came mainly from works conducted in Dr Louis Staudt’s lab (National Cancer Institute, Lymphoid Malignancies Branch, Bethesda, USA) where the outgoing phase of the global fellowship would take place. Rapid translation of basic science discovery on the BCR signalling led to the development of a specific inhibitor of a key BCR pathway adaptor named Bruton’s tyrosine kinase (BTK), which was granted for accelerated approval both in United States and Europe by regulatory medical agencies. While the potency of BCR pathway inhibitors is currently revolutionizing the management of B-cell malignancies, peripheral (ie mature) T-cell lymphomas (PTCL) still share a dismal prognosis with a 10-year overall survival barely exceeding 15%. Previous work of the experienced researcher provides strong evidence that PTCL similarly rely on T-cell receptor (TCR) signalling pathway for survival. Targeting this pathway could then lead to discovery of potent therapeutic compounds for PTCL treatment. During the 2 years of the global fellowship, the researcher would first perform a TCR pathway small hairpin RNAs (shRNAs) loss-of-function screen in PTCL cell lines in the group of Dr Louis Staudt where the technic is already available and has been fruitfully applied to B-cell malignancies. Second, the researcher would identify potential pharmacological inhibitors of the previously identified targets both in vitro and in vivo in PTCL cell lines xenograft models. This second phase of the project would take place both among the outgoing team and the return group of Pr Gilles Salles (Centre National de la Recherche Scientifique, Indolent-B-cell Proliferation Branch, Lyon, France).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TITLY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TITLY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ToMComputations (2019)

How other minds are represented in the human brain: Neural computations underlying Theory of Mind

Read More  

GENI (2019)

Gender, emotions and national identities: a new perspective on the abortion debates in Italy (1971-1981).

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More